Pharma BD Deal Intelligence
UCB is paying up big for optionality: $2.0B upfront plus $200M in milestones for Candid Therapeutics' cizutamig, a BCMAxCD3 bispecific spanning more than 10 autoimmune indications, though the deal hasn't even closed yet — antitrust clearance is still pending into Q3 2026.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers. UCB signed a definitive agreement to acquire…
UCB Expands Immunology Pipeline with Planned Acquisition of Candid Therapeutics, reinforcing its position in next-generation immunology with the addition of…
UCB inks $2B Candid buyout to join Gilead in autoimmune field. The Belgian drugmaker is buying Candid Therapeutics for $2 billion upfront with up to…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
UCB signed a definitive agreement to acquire privately held Candid Therapeutics for up to $2.2B ($2.0B upfront + $200M milestones), gaining lead asset cizutamig, a BCMAxCD3 bispecific T-cell engager in clinical development across more than 10 autoimmune indications. The deal builds UCB's immunology pipeline in B-cell-driven autoimmune diseases. Closing is anticipated in late Q2/early Q3 2026 subject to antitrust clearance.
137K US cases/yr · $2.0B 2024 US myasthenia gravis treatment market (lead indication proxy)
B-cell and plasma-cell-driven autoimmune diseases — including generalized myasthenia gravis, systemic lupus erythematosus, IgA nephropathy, and systemic sclerosis — are characterized by pathogenic autoantibody production sustained by long-lived plasma cells that current biologics (rituximab, FcRn inhibitors, complement inhibitors) cannot fully reach. Deep immune reset through BCMA-targeted plasma-cell depletion offers a curative-intent mechanism, validated by autologous CAR-T data, but with off-the-shelf T-cell engagers potentially providing broader patient access.
Autoimmune B-cell/plasma-cell depletion is a white-hot category. Cell-therapy approaches (autologous BCMA/CD19 CAR-T from Cabaletta, Kyverna, Cartesian) deliver deep reset but logistical complexity. Off-the-shelf TCEs are the scalable answer — competitors include AbbVie's CD19xCD3 (TNB-486), Roche/Genentech, Gilead/Arcellx via TCE pivot, J&J (teclistamab repositioning), and a wave of China-originated BCMAxCD3 bispecifics. UCB's existing rituximab biosimilar and FcRn franchise (Rystiggo) creates clear commercial pull-through.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| UCB S.A. / Candid Therapeutics, Inc. (this deal) | 2026 | $2.2B | — |
| UCB S.A. / Ra Pharmaceuticals, Inc. | 2019 | $2.1B | — |
| UCB S.A. / Zogenix Inc. | 2022 | $1.9B | — |
| UCB S.A. / Neurona Therapeutics, Inc. | 2026 | $1.1B | — |
| UCB S.A. / Antengene Corporation Limited | 2026 | $1.2B | — |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
← Browse all deals · How we score deals
More: 2026 deals · UCB S.A. deals · Immunology deals